Cwm LLC Lowers Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Cwm LLC cut its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 45.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 835 shares of the company’s stock after selling 683 shares during the quarter. Cwm LLC’s holdings in Medpace were worth $256,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of MEDP. SG Americas Securities LLC grew its holdings in shares of Medpace by 353.2% in the third quarter. SG Americas Securities LLC now owns 2,515 shares of the company’s stock valued at $609,000 after acquiring an additional 1,960 shares in the last quarter. Commonwealth Equity Services LLC grew its holdings in shares of Medpace by 20.2% in the third quarter. Commonwealth Equity Services LLC now owns 2,765 shares of the company’s stock valued at $669,000 after acquiring an additional 465 shares in the last quarter. Cambridge Investment Research Advisors Inc. grew its holdings in shares of Medpace by 13.3% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 3,755 shares of the company’s stock valued at $909,000 after acquiring an additional 440 shares in the last quarter. FinTrust Capital Advisors LLC bought a new position in shares of Medpace in the third quarter valued at approximately $30,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Medpace by 2.5% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,749 shares of the company’s stock valued at $1,634,000 after acquiring an additional 163 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, VP Susan E. Burwig sold 102 shares of the stock in a transaction on Friday, March 15th. The stock was sold at an average price of $403.00, for a total value of $41,106.00. Following the sale, the vice president now owns 15,181 shares in the company, valued at $6,117,943. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Medpace news, major shareholder Medpace Investors, Llc sold 13,988 shares of the firm’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $386.39, for a total transaction of $5,404,823.32. Following the sale, the insider now owns 5,525,959 shares in the company, valued at $2,135,175,298.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Susan E. Burwig sold 102 shares of the firm’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $403.00, for a total value of $41,106.00. Following the sale, the vice president now owns 15,181 shares in the company, valued at approximately $6,117,943. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 204,442 shares of company stock worth $82,702,867. Corporate insiders own 20.30% of the company’s stock.

Medpace Price Performance

Medpace stock opened at $392.57 on Friday. Medpace Holdings, Inc. has a one year low of $197.39 and a one year high of $421.00. The business has a fifty day moving average price of $398.08 and a 200-day moving average price of $330.45. The firm has a market capitalization of $12.16 billion, a P/E ratio of 40.02, a PEG ratio of 1.98 and a beta of 1.40.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, April 22nd. The company reported $3.20 EPS for the quarter, topping analysts’ consensus estimates of $2.45 by $0.75. Medpace had a return on equity of 59.74% and a net margin of 15.92%. The firm had revenue of $511.00 million during the quarter, compared to analyst estimates of $512.39 million. During the same period last year, the company earned $2.27 earnings per share. The business’s revenue for the quarter was up 17.7% on a year-over-year basis. Sell-side analysts expect that Medpace Holdings, Inc. will post 11.23 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Guggenheim upped their target price on Medpace from $453.00 to $464.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Robert W. Baird increased their price objective on Medpace from $446.00 to $454.00 and gave the company an “outperform” rating in a report on Wednesday, April 24th. Deutsche Bank Aktiengesellschaft started coverage on Medpace in a report on Monday, March 18th. They set a “hold” rating and a $395.00 price objective for the company. Jefferies Financial Group raised Medpace from a “hold” rating to a “buy” rating and increased their price objective for the company from $340.00 to $450.00 in a report on Tuesday, April 23rd. Finally, UBS Group raised Medpace from a “neutral” rating to a “buy” rating and increased their price objective for the company from $282.00 to $452.00 in a report on Thursday, February 15th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Medpace presently has an average rating of “Moderate Buy” and an average price target of $443.00.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.